Analyst Ratings for Immunogen
Portfolio Pulse from Benzinga Insights
Immunogen (NASDAQ:IMGN) has received positive analyst ratings in the last quarter, with 5 bullish and 2 somewhat bullish ratings. The average price target for the stock is $21.29, which is higher than its current price of $17.58. This average has increased by 27.71% from the previous average price target of $16.67.
August 04, 2023 | 9:49 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immunogen has received positive analyst ratings, which could potentially drive its stock price up in the short term.
Analyst ratings are a significant factor that investors consider when making investment decisions. The positive ratings for Immunogen indicate a positive outlook for the company, which could potentially lead to an increase in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100